GETUG-AFU 42, NCT06496581: Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) |
|
|
| Not yet recruiting | 3 | 500 | Europe | 177Lu-PMSA-617, Pluvicto®, Standard of Care, ADT with an ARSI (i.e. abiraterone + prednisone, or apalutamide, or enzalutamide) ± radiotherapy* or ADT with docetaxel* plus an ARSI (i.e abiraterone + prednisone, or darolutamide,) ± radiotherapy | UNICANCER, Novartis | Prostate Cancer Metastatic | 02/33 | 08/39 | | |
ReLUTH, NCT04954820: Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET |
|
|
| Recruiting | 2 | 146 | Europe | Lutathera | Institut du Cancer de Montpellier - Val d'Aurelle | Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease | 03/25 | 09/29 | | |
